 | Table 1
Nature Biotechnology
22, 3 - 4 (2004)
doi:10.1038/nbt0104-3
China approves first gene therapySue Pearson, Hepeng Jia
& Keiko Kandachi | | | | Table 1 Biotech firms with gene therapy products for cancer in phase 2 or later of clinical development | | | Company or research institute | Indication | Delivered gene | Vector | Phase of clinical development | | | | | Shenzhen SiBiono Gene Technologies (Shenzhen, China) | HNSCC | Tumor protein p53 | Adenovirus | Approved | | Shanghai Sunway Biotech (Shanghai, China) | HNSCC | HAdv5 oncolytic virus | Adenovirus | Phase 3 | | AnGes MG (Osaka, Japan) | Arteriosclerosis obliterans | Hepatocyte growth factor | Plasmid | Phase2 | | GenVec, Inc. (Gaithersburg, MD, USA) | Pancreatic, esophageal and rectal cancers | Human tumor necrosis factor-? | Adenovirus | Phase 2 | | Introgen (Austin, TX, USA) | Head and neck, lung, breast, esophageal, ovarian, bladder, brain, prostate and bronchoalveolar cancers | Tumor protein p53 | Adenovirus | Phases 1−3 | | Transgene (Strasbourg, France) | Cervical cancer | Human papilloma virus type 16 E6 and E7 antigens and interleukin 2 | Vaccinia virus | Phase 2 | | Transgene (Strasbourg, France) | Breast, lung, prostate and renal cancers | Human mucin 1 antigen and interleukin 2 | Vaccinia virus | Phase 2 | |
|
|
|
